It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Publicly available ulcerative colitis (UC) gene expression datasets from observational studies and clinical trials include inherently heterogeneous disease characteristics and methodology. We used meta-analysis to identify a robust UC gene signature from inflamed biopsies. Eight gene expression datasets derived from biopsy tissue samples from noninflammatory bowel disease (IBD) controls and areas of active inflammation from patients with UC were publicly available. Expression- and meta-data were downloaded with GEOquery. Differentially expressed genes (DEG) in individual datasets were defined as those with fold change > 1.5 and a Benjamini–Hochberg adjusted P value < .05. Meta-analysis of all DEG used a random effects model. Reactome pathway enrichment analysis was conducted. Meta-analysis identified 946 up- and 543 down-regulated genes in patients with UC compared to non-IBD controls (1.2 and 1.7 times fewer up- and down-regulated genes than the median of the individual datasets). Top-ranked up- and down-regulated DEG were LCN2 and AQP8. Multiple immune-related pathways (e.g., ‘Chemokine receptors bind chemokine’ and ‘Interleukin-10 signaling’) were significantly up-regulated in UC, while ‘Biological oxidations’ and ‘Fatty acid metabolism’ were downregulated. A web-based data-mining tool with the meta-analysis results was made available (https://premedibd.com/genes.html). A UC inflamed biopsy disease gene signature was derived. This signature may be an unbiased reference for comparison and improve the efficiency of UC biomarker studies by increasing confidence for identification of disease-related genes and pathways.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Alimentiv, Inc, London, Canada
2 Alimentiv, Inc, London, Canada; University of Western Ontario, Department of Medicine, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884); University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884)
3 Alimentiv, Inc, London, Canada (GRID:grid.39381.30); University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884)
4 Alimentiv, Inc, London, Canada (GRID:grid.39381.30)
5 F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
6 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain (GRID:grid.10403.36)
7 University Hospitals Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338); Translational Research in Gastrointestinal Disorders (TARGID) - IBD Unit, KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
8 University of Toronto, Mount Sinai Hospital Inflammatory Bowel Disease Centre, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
9 Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Zane Cohen Centre for Digestive Diseases, Toronto, Canada (GRID:grid.250674.2) (ISNI:0000 0004 0626 6184)
10 Alimentiv, Inc, London, Canada (GRID:grid.250674.2); University of Western Ontario, Department of Medicine, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884); University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884)
11 Alimentiv, Inc, London, Canada (GRID:grid.39381.30); University of California San Diego, IBD Center, Division of Gastroenterology, Department of Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)